Literature DB >> 20155624

Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies.

Naghma Khan1, Vaqar Mustafa Adhami, Hasan Mukhtar.   

Abstract

The prevention of prostate cancer (PCa) is a crucial medical challenge in developed countries. PCa remains surrounded by puzzles in spite of the considerable progress in research, diagnosis, and treatment. It is an ideal target for chemoprevention, as clinically significant PCa usually requires more than two decades for development. Green tea and its major constituent epigallocatechin gallate (EGCG) have been extensively studied as a potential treatment for a variety of diseases including cancer. In this review, we highlight the evidences of green tea polyphenols from preclinical and clinical studies in the chemoprevention/chemotherapy of PCa.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20155624      PMCID： PMC2991093          DOI： 10.1080/01635580903285056

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN： 0163-5581            Impact factor:   2.900


  39 in total

1.  A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma.

Authors:  Aminah Jatoi; Neil Ellison; Patrick A Burch; Jeff A Sloan; Shaker R Dakhil; Paul Novotny; Winston Tan; Tom R Fitch; Kendrith M Rowland; Charles Y F Young; Patrick J Flynn
Journal:  Cancer       Date:  2003-03-15       Impact factor: 6.860

2.  A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach.

Authors:  E Choan; Roanne Segal; Derek Jonker; Shawn Malone; Neil Reaume; Libni Eapen; Victor Gallant
Journal:  Urol Oncol       Date:  2005 Mar-Apr       Impact factor: 3.498

3.  Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study.

Authors:  Saverio Bettuzzi; Maurizio Brausi; Federica Rizzi; Giovanni Castagnetti; Giancarlo Peracchia; Arnaldo Corti
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

Review 4.  Clinical relevance of the inhibitory effect of green tea catechins (GtCs) on prostate cancer progression in combination with molecular profiling of catechin-resistant tumors: an integrated view.

Authors:  S Bettuzzi; F Rizzi; L Belloni
Journal:  Pol J Vet Sci       Date:  2007       Impact factor: 0.821

5.  Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo.

Authors:  Vaqar Mustafa Adhami; Arshi Malik; Najia Zaman; Sami Sarfaraz; Imtiaz Ahmad Siddiqui; Deeba Nadeem Syed; Farrukh Afaq; Farrukh Sierre Pasha; Mohammad Saleem; Hasan Mukhtar
Journal:  Clin Cancer Res       Date:  2007-03-01       Impact factor: 12.531

6.  Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.

Authors:  I A Siddiqui; A Malik; V M Adhami; M Asim; B B Hafeez; S Sarfaraz; H Mukhtar
Journal:  Oncogene       Date:  2007-11-12       Impact factor: 9.867

7.  Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells.

Authors:  Koen Brusselmans; Ellen De Schrijver; Walter Heyns; Guido Verhoeven; Johannes V Swinnen
Journal:  Int J Cancer       Date:  2003-10-10       Impact factor: 7.396

8.  The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression.

Authors:  Andrea Caporali; Pierpaola Davalli; Serenella Astancolle; Domenico D'Arca; Maurizio Brausi; Saverio Bettuzzi; Arnaldo Corti
Journal:  Carcinogenesis       Date:  2004-09-09       Impact factor: 4.944

9.  Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells.

Authors:  Kedar Hastak; Sanjay Gupta; Nihal Ahmad; Mukesh K Agarwal; Munna L Agarwal; Hasan Mukhtar
Journal:  Oncogene       Date:  2003-07-31       Impact factor: 9.867

Review 10.  Tea polyphenols for health promotion.

Authors:  Naghma Khan; Hasan Mukhtar
Journal:  Life Sci       Date:  2007-06-28       Impact factor: 5.037
View more
  47 in total

1.  Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention.

Authors:  Nagi B Kumar; Julio Pow-Sang; Kathleen M Egan; Philippe E Spiess; Shohreh Dickinson; Raoul Salup; Mohamed Helal; Jerry McLarty; Christopher R Williams; Fred Schreiber; Howard L Parnes; Said Sebti; Aslam Kazi; Loveleen Kang; Gwen Quinn; Tiffany Smith; Binglin Yue; Karen Diaz; Ganna Chornokur; Theresa Crocker; Michael J Schell
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-14

2.  Autoxidation of gallic acid induces ROS-dependent death in human prostate cancer LNCaP cells.

Authors:  Larry H Russell; Elizabeth Mazzio; Ramesh B Badisa; Zhi-Ping Zhu; Maryam Agharahimi; Ebenezer T Oriaku; Carl B Goodman
Journal:  Anticancer Res       Date:  2012-05       Impact factor: 2.480

Review 3.  The strategies to control prostate cancer by chemoprevention approaches.

Authors:  Harold Ting; Gagan Deep; Chapla Agarwal; Rajesh Agarwal
Journal:  Mutat Res       Date:  2014-01-02       Impact factor: 2.433

Review 4.  Dietary agents for prevention and treatment of lung cancer.

Authors:  Naghma Khan; Hasan Mukhtar
Journal:  Cancer Lett       Date:  2015-01-30       Impact factor: 8.679

5.  A Placebo-Controlled Double-Blinded Randomized Pilot Study of Combination Phytotherapy in Biochemically Recurrent Prostate Cancer.

Authors:  M Diana van Die; Scott G Williams; Jon Emery; Kerry M Bone; Jeremy M G Taylor; Elizabeth Lusk; Marie V Pirotta
Journal:  Prostate       Date:  2017-02-09       Impact factor: 4.104

6.  Anti-inflammatory effect of the epigallocatechin gallate following spinal cord trauma in rat.

Authors:  Ali Reza Khalatbary; Hassan Ahmadvand
Journal:  Iran Biomed J       Date:  2011

Review 7.  Targeting CSC-related miRNAs for cancer therapy by natural agents.

Authors:  Bin Bao; Yiwei Li; Aamir Ahmad; Asfar S Azmi; Ginny Bao; Shadan Ali; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Curr Drug Targets       Date:  2012-12       Impact factor: 3.465

8.  Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia.

Authors:  D Altavilla; L Minutoli; F Polito; N Irrera; S Arena; C Magno; M Rinaldi; B P Burnett; F Squadrito; A Bitto
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 9.  Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer.

Authors:  Harold Ting; Gagan Deep; Rajesh Agarwal
Journal:  AAPS J       Date:  2013-04-16       Impact factor: 4.009

10.  The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition.

Authors:  Su-Ni Tang; Chandan Singh; Dara Nall; Daniel Meeker; Sharmila Shankar; Rakesh K Srivastava
Journal:  J Mol Signal       Date:  2010-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.